Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses

International Journal of Pharmaceutics

Volumn 379, Issue 1-2, 2009, Pages 41-50

  Thomas, Chandan ^a   Gupta, Vivek ^a   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bronchoalveolar lavage; Hepatitis B surface antigen; Microspheres; Mucosal delivery; Poly(d,l lactic co glycolic acid); Vaccine delivery

Indexed keywords

CYTOKINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; MICROSPHERE; OCTADECYLAMINE; POLYETHYLENEIMINE; POLYGLACTIN; RECOMBINANT ANTIGEN; SECRETORY IMMUNOGLOBULIN; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; EMULSION; EVAPORATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; LUNG LAVAGE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SALIVA LEVEL; SPLEEN; SURFACE CHARGE; TISSUE HOMOGENATE; TISSUE LEVEL; ZETA POTENTIAL;

ADMINISTRATION, INHALATION; AMINES; ANIMALS; BRONCHI; CELL LINE; CELL SURVIVAL; CYTOKINES; DELAYED-ACTION PREPARATIONS; EPITHELIAL CELLS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; LACTIC ACID; MICROSPHERES; PARTICLE SIZE; POLYETHYLENEIMINE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 68649083210     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.06.006     Document Type: Article

References (44)

1. Amidi M., Pellikaan H.C., Hirschberg H., de Boer A.H., Crommelin D.J., Hennink W.E., Kersten G., and Jiskoot W. Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine 25 (2007) 6818-6829
2. Amorij J.P., Saluja V., Petersen A.H., Hinrichs W.L., Huckriede A., and Frijlink H.W. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 25 (2007) 8707-8717
3. Azzali G. Structure, lymphatic vascularization and lymphocyte migration in mucosa-associated lymphoid tissue. Immunol. Rev. 195 (2003) 178-189
4. Bivas-Benita M., Ottenhoff T.H., Junginger H.E., and Borchard G. Pulmonary DNA vaccination: concepts, possibilities and perspectives. J. Control. Rel. 107 (2005) 1-29
5. Brewer J.M., Pollock K.G., Tetley L., and Russell D.G. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J. Immunol. 173 (2004) 6143-6150
6. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13 (1995) 29-60
7. Constant S.L., and Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15 (1997) 297-322
8. Cui Z., and Mumper R.J. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J. Pharm. Pharmacol. 54 (2002) 1195-1203
9. Debin A., Kravtzoff R., Santiago J.V., Cazales L., Sperandio S., Melber K., Janowicz Z., Betbeder D., and Moynier M. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20 (2002) 2752-2763
10. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., and Langer R. Large porous particles for pulmonary drug delivery. Science 276 (1997) 1868-1871
11. Feng L., Qi X.R., Zhou X.J., Maitani Y., Wang S.C., Jiang Y., and Nagai T. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Rel. 112 (2006) 35-42
12. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F., and Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173 (2004) 3148-3154
13. Gupta P.N., Khatri K., Goyal A.K., Mishra N., and Vyas S.P. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target. 15 (2007) 701-713
14. Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., and Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21 (2002) 67-77
15. Jaganathan K.S., Singh P., Prabakaran D., Mishra V., and Vyas S.P. Development of a single-dose stabilized poly(d,l-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. J. Pharm. Pharmacol. 56 (2004) 1243-1250
16. Jaganathan K.S., and Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24 (2006) 4201-4211
17. Katare Y.K., Muthukumaran T., and Panda A.K. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int. J. Pharm. 301 (2005) 149-160
18. Lee S.C., Oh J.T., Jang M.H., and Chung S.I. Quantitative analysis of polyvinyl alcohol on the surface of poly(d,l-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. J. Control. Rel. 59 (1999) 123-132
19. Li X., Kong X., Shi S., Zheng X., Guo G., Wei Y., and Qian Z. Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol. 8 (2008) 89
20. Lu D., and Hickey A.J. Pulmonary vaccine delivery. Expert Rev. Vaccines 6 (2007) 213-226
21. Ma R., Du J.L., Huang J., and Wu C.Y. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem. Biophys. Res. Commun. 361 (2007) 537-542
22. MacDonald T.T. The mucosal immune system. Parasite Immunol. 25 (2003) 235-246
23. McCluskie M.J., and Davis H.L. Mucosal immunization with DNA vaccines. Microbes Infect./Institut Pasteur. 1 (1999) 685-698
24. McDermott M.R., and Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122 (1979) 1892-1898
25. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7 (1987) 265-276
26. Nagler-Anderson C. Man the barrier! Strategic defences in the intestinal mucosa. Nat. Rev. Immunol. 1 (2001) 59-67
27. Nellore R.V., Pande P.G., Young D., and Bhagat H.R. Evaluation of biodegradable microspheres as vaccine adjuvant for hepatitis B surface antigen. J. Parenter. Sci. Technol. 46 (1992) 176-180
28. Ogra P.L., Faden H., and Welliver R.C. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14 (2001) 430-445
29. Pandit S., Cevher E., Zariwala M.G., Somavarapu S., and Alpar H.O. Enhancement of immune response of HBsAg loaded poly(l-lactic acid) microspheres against hepatitis B through incorporation of alum and chitosan. J. Microencapsul. 24 (2007) 539-552
30. Patton J.S. Mechanisms of macromolecules absorption by the lungs. Adv. Drug Deliv. Rev. 19 (1996) 3-36
31. Patton J.S., Fishburn C.S., and Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1 (2004) 338-344
32. Rawat A., Majumder Q.H., and Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J. Control. Rel. 128 (2008) 224-232
33. Rosenthal K.L., and Gallichan W.S. Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin. Immunol. 9 (1997) 303-314
34. Shi L., Caulfield M.J., Chern R.T., Wilson R.A., Sanyal G., and Volkin D.B. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J. Pharm. Sci. 91 (2002) 1019-1035
35. Singh M., Briones M., Ott G., and O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 811-816
36. Smith D.J., Bot S., Dellamary L., and Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 21 (2003) 2805-2812
37. Thiele L., Merkle H.P., and Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm. Res. 20 (2003) 221-228
38. Thomas, C., 2009. PhD Dissertation, Respirable particulate carriers for pulmonary delivery of hepatitis B vaccine. Texas Tech University Health Sciences Center, Texas USA.
39. Thomas C., Rawat A., Bai S., and Ahsan F. Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside. J. Pharm. Sci. 97 (2008) 1213-1223
40. Ungaro F., De Rosa G., Miro A., Quaglia F., and La Rotonda M.I. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur. J. Pharm. Sci. 28 (2006) 423-432
41. Vyas S.P., Singh R.P., Jain S., Mishra V., Mahor S., Singh P., Gupta P.N., Rawat A., and Dubey P. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int. J. Pharm. 296 (2005) 80-86
42. Wee S., and Gombotz W.R. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31 (1998) 267-285
43. Wischke C., Borchert H.H., Zimmermann J., Siebenbrodt I., and Lorenzen D.R. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J. Control. Rel. 114 (2006) 359-368
44. Yang Y.Y., Chung T.S., and Ng N.P. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22 (2001) 231-241